Cree/ATP Assay Ovarian Trial, ASCO ‘05
n.s.
68%
54%
PR + CR + SD
(%)
n.s.
42%
34%
PR + CR (%)
n.s.
32%
46%
Progressive
Disease
n.s.
25%
21%
Stable
Disease
(SD)
n.s.
34%
26%
Partial
Response
(PR)
not
significant
8%
7%
Complete
Remission
(CR)
P Value
ATP Assay-
Directed
Clinician’s
Choice
Treatment
Effect